NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director James N. Topper Buys 471 Shares

Key Points

• James N. Topper, a director at NewAmsterdam Pharma, purchased 471 shares of the company on August 11th, increasing his ownership to over 3 million shares valued at approximately $72.6 million.
• NewAmsterdam Pharma reported a quarterly earnings per share of ($0.15), exceeding analyst expectations, and generated $19.15 million in revenue for the quarter.
• Most analysts maintain a consensus rating of "Moderate Buy" for NewAmsterdam Pharma, with target prices ranging from $27.00 to $42.00.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) Director James N. Topper purchased 471 shares of the firm's stock in a transaction dated Monday, August 11th. The stock was purchased at an average cost of $23.98 per share, with a total value of $11,294.58. Following the acquisition, the director directly owned 3,026,604 shares in the company, valued at $72,577,963.92. This trade represents a 0.02% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS traded up $0.76 on Wednesday, hitting $25.76. 579,881 shares of the company's stock were exchanged, compared to its average volume of 879,871. The firm has a 50-day moving average price of $20.96 and a 200-day moving average price of $20.02. NewAmsterdam Pharma Company N.V. has a 52 week low of $14.06 and a 52 week high of $27.29. The company has a market cap of $2.89 billion, a P/E ratio of -15.90 and a beta of -0.02.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.37. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. The company had revenue of $19.15 million during the quarter, compared to the consensus estimate of $1.44 million. On average, research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of NewAmsterdam Pharma in a report on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 price target for the company. Wall Street Zen raised shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research note on Saturday, July 5th. Needham & Company LLC reaffirmed a "buy" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th. The Goldman Sachs Group initiated coverage on shares of NewAmsterdam Pharma in a research note on Thursday, July 17th. They issued a "neutral" rating and a $27.00 target price for the company. Finally, Citigroup initiated coverage on shares of NewAmsterdam Pharma in a research note on Tuesday, June 17th. They issued a "buy" rating and a $42.00 target price for the company. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $41.20.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several hedge funds have recently bought and sold shares of the company. Quarry LP bought a new position in NewAmsterdam Pharma in the 1st quarter valued at about $25,000. GF Fund Management CO. LTD. bought a new position in NewAmsterdam Pharma in the 4th quarter valued at about $50,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in NewAmsterdam Pharma by 18.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company's stock valued at $79,000 after acquiring an additional 662 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in NewAmsterdam Pharma by 130.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock valued at $123,000 after acquiring an additional 3,390 shares during the period. Finally, Avanza Fonder AB bought a new position in NewAmsterdam Pharma in the 1st quarter valued at about $127,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.